Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2005 1
2006 2
2007 1
2008 1
2011 1
2012 2
2013 4
2014 1
2015 2
2016 1
2017 4
2018 1
2019 5
2020 6
2021 4
2022 3
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC.
Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, Zhou C, Reungwetwattana T, Cheng Y, Chewaskulyong B, Shah R, Cobo M, Lee KH, Cheema P, Tiseo M, John T, Lin MC, Imamura F, Kurata T, Todd A, Hodge R, Saggese M, Rukazenkov Y, Soria JC; FLAURA Investigators. Ramalingam SS, et al. N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21. N Engl J Med. 2020. PMID: 31751012 Free article. Clinical Trial.
Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease.
Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Salloway S, et al. N Engl J Med. 2014 Jan 23;370(4):322-33. doi: 10.1056/NEJMoa1304839. N Engl J Med. 2014. PMID: 24450891 Free PMC article. Clinical Trial.
Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.
Hill MD, Goyal M, Menon BK, Nogueira RG, McTaggart RA, Demchuk AM, Poppe AY, Buck BH, Field TS, Dowlatshahi D, van Adel BA, Swartz RH, Shah RA, Sauvageau E, Zerna C, Ospel JM, Joshi M, Almekhlafi MA, Ryckborst KJ, Lowerison MW, Heard K, Garman D, Haussen D, Cutting SM, Coutts SB, Roy D, Rempel JL, Rohr AC, Iancu D, Sahlas DJ, Yu AYX, Devlin TG, Hanel RA, Puetz V, Silver FL, Campbell BCV, Chapot R, Teitelbaum J, Mandzia JL, Kleinig TJ, Turkel-Parrella D, Heck D, Kelly ME, Bharatha A, Bang OY, Jadhav A, Gupta R, Frei DF, Tarpley JW, McDougall CG, Holmin S, Rha JH, Puri AS, Camden MC, Thomalla G, Choe H, Phillips SJ, Schindler JL, Thornton J, Nagel S, Heo JH, Sohn SI, Psychogios MN, Budzik RF, Starkman S, Martin CO, Burns PA, Murphy S, Lopez GA, English J, Tymianski M; ESCAPE-NA1 Investigators. Hill MD, et al. Lancet. 2020 Mar 14;395(10227):878-887. doi: 10.1016/S0140-6736(20)30258-0. Epub 2020 Feb 20. Lancet. 2020. PMID: 32087818 Clinical Trial.
Pulmonary embolism diagnostic strategies in patients with COPD exacerbation: Post-hoc analysis of the PEP trial.
Rambaud G, Mai V, Motreff C, Sanchez O, Roy PM, Auffret Y, Le Mao R, Gagnadoux F, Paleiron N, Schmidt J, Pastre J, Nonent M, Tromeur C, Salaun PY, Mismetti P, Girard P, Lacut K, Lemarié CA, Meyer G, Leroyer C, Le Gal G, Bertoletti L, Couturaud F; “PEP” investigators. Rambaud G, et al. Thromb Res. 2023 Nov;231:58-64. doi: 10.1016/j.thromres.2023.09.013. Epub 2023 Sep 28. Thromb Res. 2023. PMID: 37806116
AIMS: To evaluate the safety and efficacy of standard (revised Geneva and Wells PE scores combined with fixed D-dimer cut-off) and computed tomography pulmonary angiogram (CTPA)-sparing diagnostic strategies (ADJUST-PE, YEARS, PEGeD, 4PEPS) in patients with AE-COPD. ...All …
AIMS: To evaluate the safety and efficacy of standard (revised Geneva and Wells PE scores combined with fixed D-dimer cut-off) and co …
Mediation of Age and Thrombectomy Outcome by Neuroimaging Markers of Frailty in Patients With Stroke.
Benali F, Singh N, Fladt J, Jaroenngarmsamer T, Bala F, Ospel JM, Buck BH, Dowlatshahi D, Field TS, Hanel RA, Peeling L, Tymianski M, Hill MD, Goyal M, Ganesh A; ESCAPE-NA1 Investigators. Benali F, et al. JAMA Netw Open. 2024 Jan 2;7(1):e2349628. doi: 10.1001/jamanetworkopen.2023.49628. JAMA Netw Open. 2024. PMID: 38165676 Free PMC article. Clinical Trial.
Defining ELISpot cut-offs from unreplicated test and control wells.
Alexander N, Fox A, Lien VT, Dong T, Lee LY, Hang Nle K, Mai le Q, Horby P. Alexander N, et al. J Immunol Methods. 2013 Jun 28;392(1-2):57-62. doi: 10.1016/j.jim.2013.02.014. Epub 2013 Mar 7. J Immunol Methods. 2013. PMID: 23500146 Free PMC article.
In the absence of replication of wells, empirical criteria for enzyme-linked immunospot (ELISpot) positivity use fixed differences or ratios between spot forming units (SFU) counts between test and control. ...This method is illustrated using 1309 assay results from a coho …
In the absence of replication of wells, empirical criteria for enzyme-linked immunospot (ELISpot) positivity use fixed differences or …
Development of a robotics platform for automated multi-ionization mass spectrometry.
Karki S, Meher AK, Inutan ED, Pophristic M, Marshall DD, Rackers K, Trimpin S, McEwen CN. Karki S, et al. Rapid Commun Mass Spectrom. 2021 Jan;35 Suppl 1:e8449. doi: 10.1002/rcm.8449. Epub 2019 Jun 4. Rapid Commun Mass Spectrom. 2021. PMID: 30950108
RESULTS: A comparison study of a mixture of angiotensin I, verapamil, crystal violet, and atrazine representative of peptides, drugs, dyes, and herbicides using SAI, MAI, and ESI shows large differences in ionization efficiency of the various components. Solutions of a mix …
RESULTS: A comparison study of a mixture of angiotensin I, verapamil, crystal violet, and atrazine representative of peptides, drugs, dyes, …
Fluoride: A naturally-occurring health hazard in drinking-water resources of Northern Thailand.
Chuah CJ, Lye HR, Ziegler AD, Wood SH, Kongpun C, Rajchagool S. Chuah CJ, et al. Sci Total Environ. 2016 Mar 1;545-546:266-79. doi: 10.1016/j.scitotenv.2015.12.069. Epub 2015 Dec 31. Sci Total Environ. 2016. PMID: 26747991
At the Chiang Mai site, 31% of the shallow wells contained hazardous levels ( 1.5 mg/L) of fluoride, compared with the 18% observed in the deep wells. However, at the Lamphun site, more deep wells (35%) contained water with at least 1.5mg/L fluo …
At the Chiang Mai site, 31% of the shallow wells contained hazardous levels ( 1.5 mg/L) of fluoride, compared with the 18% obs …
44 results